Terns Pharmaceuticals (TERN) has had the highest return this quarter by a mid-cap US stock, returning 526.2%.

ASSET	QUARTER	% RETURN
Terns Pharmaceuticals (TERN)	Q4 2025	526.2%
Praxis Precision Medicines (PRAX)	Q4 2025	406.79%
Olema Pharmaceuticals (OLMA)	Q4 2025	220.28%
Cogent Biosciences (COGT)	Q4 2025	183.97%
PACS (PACS)	Q4 2025	146.35%
Structure Therapeutics Inc American Depositary Shares (GPCR)	Q4 2025	141.03%
Fluence Energy (FLNC)	Q4 2025	134.45%
Cidara Therapeutics (CDTX)	Q4 2025	130.57%
Wave Life Sciences (WVE)	Q4 2025	128.51%
Nuvation Bio (NUVB)	Q4 2025	121.42%
Sandisk (SNDK)	Q4 2025	113.7%
Banco Macro SA B ADR (BMA)	Q4 2025	107.83%
Vicor (VICR)	Q4 2025	105.56%
Spyre Therapeutics (SYRE)	Q4 2025	105.38%
Celcuity LLC (CELC)	Q4 2025	105.32%
Arrowhead Pharmaceuticals (ARWR)	Q4 2025	105.04%
Globalstar, Inc Common Stock (GSAT)	Q4 2025	104.95%
Central Puerto (CEPU)	Q4 2025	104.33%
Belite Bio Inc ADR (BLTE)	Q4 2025	103.42%
BBVA Banco Frances SA ADR (BBAR)	Q4 2025	99.01%
Apogee Therapeutics, Inc Common Stock (APGE)	Q4 2025	93.45%
Victoria's Secret (VSCO)	Q4 2025	92.45%
Arcus Biosciences (RCUS)	Q4 2025	87.33%
Inspire Medical Systems (INSP)	Q4 2025	84.24%
Grupo Financiero Galicia SA ADR (GGAL)	Q4 2025	78.03%

Mid-cap stocks are treated as having a market cap between $2B and $10B.